[go: up one dir, main page]

GB2451599A - Nanostructures suitable for delivery of agents - Google Patents

Nanostructures suitable for delivery of agents Download PDF

Info

Publication number
GB2451599A
GB2451599A GB0821019A GB0821019A GB2451599A GB 2451599 A GB2451599 A GB 2451599A GB 0821019 A GB0821019 A GB 0821019A GB 0821019 A GB0821019 A GB 0821019A GB 2451599 A GB2451599 A GB 2451599A
Authority
GB
United Kingdom
Prior art keywords
delivery
nanolattices
agents
pharmaceutical agents
nanostructures suitable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0821019A
Other versions
GB0821019D0 (en
Inventor
Gregory J Russell-Jones
Michael R Luke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apollo Life Science Ltd
Original Assignee
Apollo Life Science Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apollo Life Science Ltd filed Critical Apollo Life Science Ltd
Publication of GB0821019D0 publication Critical patent/GB0821019D0/en
Publication of GB2451599A publication Critical patent/GB2451599A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel nanolattices comprising cross-linked or chelated polymers having a desired polydispersity index suitable for delivery of pharmaceutical agents and complexes comprising same are described. Methods of making the nanolattices and use of the nanolattices to deliver pharmaceutical agents for use in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications are also described.
GB0821019A 2006-05-16 2008-11-17 Nanostructures suitable for delivery of agents Withdrawn GB2451599A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80089806P 2006-05-16 2006-05-16
PCT/AU2007/000655 WO2007131286A1 (en) 2006-05-16 2007-05-16 Nanostructures suitable for delivery of agents

Publications (2)

Publication Number Publication Date
GB0821019D0 GB0821019D0 (en) 2008-12-24
GB2451599A true GB2451599A (en) 2009-02-04

Family

ID=38693454

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0821019A Withdrawn GB2451599A (en) 2006-05-16 2008-11-17 Nanostructures suitable for delivery of agents

Country Status (3)

Country Link
AU (1) AU2007250536A1 (en)
GB (1) GB2451599A (en)
WO (1) WO2007131286A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993437B2 (en) 2007-12-06 2018-06-12 The Regents Of The University Of California Mesoporous silica nanoparticles for biomedical applications
WO2011046983A2 (en) 2009-10-12 2011-04-21 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
US20120207795A1 (en) 2010-07-13 2012-08-16 The Regents Of The University Of California Cationic polymer coated mesoporous silica nanoparticles and uses thereof
CN103501821A (en) 2011-03-08 2014-01-08 艾克塞斯制药公司 Targeted nanocarrier systems for delivery of actives across biological membranes
US10220004B2 (en) 2011-07-14 2019-03-05 The Regents Of The University Of California Method of controlled delivery using sub-micron-scale machines
CA2908154C (en) 2013-04-29 2023-11-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
CA2931547A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
FR3054444A1 (en) * 2016-07-29 2018-02-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies ORAL COMPOSITION OF ANTI-TNF ALPHA ANTIBODY
BR112021015101A2 (en) * 2019-02-04 2021-10-05 Dsm Ip Assets B.V. THERAPEUTIC COMBINATIONS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (II)
WO2020219445A1 (en) 2019-04-22 2020-10-29 Ian Basil Shine Preventing and treating malaria
WO2025096900A1 (en) * 2023-11-03 2025-05-08 Board Of Regents, The University Of Texas System Synthetic network materials and methods of making and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855127A (en) * 1986-07-07 1989-08-08 Dow Corning Corporation Lattice-entrapped composition
US6482413B1 (en) * 2001-02-26 2002-11-19 Council Of Scientific And Industrial Research Vitamin B12 —biodegradable micro particulate conjugate carrier systems for peroral delivery of drugs, therapeutic peptides/proteins and vaccines
US7153525B1 (en) * 2000-03-22 2006-12-26 The University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855127A (en) * 1986-07-07 1989-08-08 Dow Corning Corporation Lattice-entrapped composition
US7153525B1 (en) * 2000-03-22 2006-12-26 The University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
US6482413B1 (en) * 2001-02-26 2002-11-19 Council Of Scientific And Industrial Research Vitamin B12 —biodegradable micro particulate conjugate carrier systems for peroral delivery of drugs, therapeutic peptides/proteins and vaccines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
International Journal of Pharmaceutics (1999) 190:165-174 *
Journal of Controlled Release (2006) 65:49-54 *
Journal of Controlled Release (2007) 117:421-429 *
Journal of Drug Targeting (2004) 12:(2) 113-23 *

Also Published As

Publication number Publication date
AU2007250536A1 (en) 2007-11-22
GB0821019D0 (en) 2008-12-24
WO2007131286A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
GB2451599A (en) Nanostructures suitable for delivery of agents
WO2007146426A3 (en) Nanoshells for drug delivery
TW200605870A (en) Topical methadone compositions and methods for using the same
MXPA03005863A (en) Breathable, biodegradable/compostable laminates.
WO2008101214A3 (en) Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
WO2005051316A3 (en) Polymer compositions and methods for their use
EP2759302A3 (en) 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour
EP2669269A3 (en) Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
WO2008036144A3 (en) Nanoshells on polymers
WO2002047668A3 (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
WO2007112403A3 (en) Prevention and treatment of ischemia-reperfusion injury
WO2007050784A3 (en) Fixed ratio drug combination treatments for solid tumors
AU2003267581A1 (en) Drug delivery
GEP20115231B (en) 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidin-5-ones
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
IL201730A (en) Derivatives of 1h-benzoimidazol-2-yl-propyl-methyl-amino-ethyl-5-aryl-bicyclo[2.2.2]oct-5-en-2-ol, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
WO2006017245A3 (en) Sulfonated styrene polymers for medical articles
EP2161037A3 (en) Camptothecin-Somatostatin conjugates
PL369148A1 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
TW200641025A (en) Reverse phase hydrophilic polymers and their use in water-expandandable elastomeric compositions
WO2007149804A3 (en) Lactam polymer derivatives
GB2476418A (en) A medicinal product and treatment
EP1643999B8 (en) Pyridoxamine for use in the treatment of diabetic nephropathy in type ii diabetes
EP1831266A4 (en) Crosslinked amine polymers
TW200603727A (en) Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)